rss
Heart 95:704-708 doi:10.1136/hrt.2008.154054
  • Original article
  • Heart rhythm disorders and pacemakers

Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial

  1. C N Pellegrini1,
  2. E Vittinghoff2,
  3. F Lin2,
  4. S B Hulley2,
  5. G M Marcus1
  1. 1
    Division of Cardiology, Electrophysiology Section, University of California, San Francisco, California, USA
  2. 2
    Department of Epidemiology and Biostatics, University of California, San Francisco, California, USA
  1. Dr G M Marcus, 500 Parnassus Avenue, Room MUE434, Box 1354, San Francisco, CA 94143-1354, USA; marcusg{at}medicine.ucsf.edu
  • Accepted 14 October 2008
  • Published Online First 28 January 2009

Abstract

Objective: To determine the efficacy of statin treatment in atrial fibrillation (AF) prevention in women.

Design: Cohort study using data obtained in the Heart and Estrogen/Progestin Replacement Study (HERS).

Setting: Secondary analysis of a multicentre, randomised controlled clinical trial.

Patients: 2673 Postmenopausal women with coronary disease.

Main outcome measures: AF prevalence at baseline and incident AF over a mean follow-up of 4.1 years.

Results: 88 Women with AF were identified: 29 at baseline and 59 during follow-up. Women with AF were significantly less likely to be taking a statin at study enrolment than those without AF (22% vs 37%, p = 0.003). Baseline statin use was associated with a 65% lower odds of having AF at baseline after controlling for age, race, history of myocardial infarction or revascularisation and history of heart failure (odds ratio 0.35, 95% confidence interval (CI) 0.13 to 0.93, p = 0.04). The risk of developing AF during the study among those free from AF at baseline, adjusted for the same covariates, was 55% less for those receiving statin treatment (hazard ratio 0.45, 95% CI 0.26 to 0.78, p = 0.004).

Conclusions: Statin treatment is associated with a lower prevalence and incidence of AF after adjustment for potential confounders in postmenopausal women with coronary disease.

Footnotes

  • Funding: This work was made possible by a fellowship grant from the American Heart Association Western States Affiliate (CNP), grant number KL2 RR024130 from the National Center for Research Resources, a component of the NIH (GMM), and an American Heart Association Beginning Grant-in-Aid Award (GMM).

  • Competing interests: None.

  • Ethics approval: Ethics committee approval obtained.

Relevant Article

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Heart.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article